论文信息 - P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results - 字舞流文

P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results

D. Selkoe | L. Honigberg | U. Eichenlaub | T. Duning | S. Ostrowitzki | D. Clayton | T. Bittner | C. Rabe | A. Quartino | S. S. Bohorquez | M. Rabbia | H. Shimizu | J. Smith | N. Hu

[1] D. Selkoe,et al. Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid , 2019, Annals of neurology.

[2] S. Salloway,et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE) , 2018, Alzheimer's Research & Therapy.

[3] J. Cummings,et al. ABBY , 2018, Neurology.

[4] M. Ultsch,et al. Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin , 2016, Scientific Reports.